PMID- 34379177
OWN - NLM
STAT- MEDLINE
DCOM- 20220228
LR  - 20240426
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Print)
IS  - 0340-7004 (Linking)
VI  - 71
IP  - 3
DP  - 2022 Mar
TI  - Effect of HLA genotype on intravesical recurrence after bacillus Calmette-Guerin 
      therapy for non-muscle-invasive bladder cancer.
PG  - 727-736
LID - 10.1007/s00262-021-03032-0 [doi]
AB  - The intravesical administration of bacillus Calmette-Guerin (BCG) is widely used 
      to control the intravesical recurrence of non-muscle-invasive bladder cancer 
      (NMIBC). This study aimed to reveal the effects of zygosity on human leukocyte 
      antigen (HLA) genes and individual HLA genotypes on intravesical recurrence after 
      intravesical BCG therapy for NMIBC. This study included Japanese patients who had 
      received intravesical BCG for NMIBC. HLA genotyping of HLA-A, B, C, and DRB1 was 
      performed. The effect of HLA zygosity and HLA genotype on intravesical recurrence 
      was evaluated. Among 195 patients, those homozygous for the HLA-B supertype were 
      more likely than those heterozygous for the HLA-B supertype to experience 
      intravesical recurrence by univariate analysis (hazard ratio [HR], 95% confidence 
      interval [CI]; 1.87, 1.14-3.05, P = 0.012) and multivariate analysis (HR, 95% CI; 
      2.26, 1.02-5.01, P = 0.045). Patients with B07 or B44 had a decreased risk of 
      intravesical recurrence by univariate analysis (HR, 95% CI; 0.43, 0.24-0.78, 
      P = 0.0056) and multivariate analysis (HR, 95% CI; 0.36, 0.16-0.82, P = 0.016). 
      This study suggests the importance of the diversity and specificity of HLA-B loci 
      in the antitumor effect of BCG immunotherapy for NMIBC. These findings may 
      contribute to the delineation of risk strata for BCG therapy and improve the 
      medical management of NMIBC.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Kobayashi, Mizuki
AU  - Kobayashi M
AD  - Department of Urology, Graduate School of Medicine, Akita University, Akita, 
      010-8543, Japan.
FAU - Fujiyama, Nobuhiro
AU  - Fujiyama N
AD  - Center for Kidney Disease and Transplantation, Akita University Hospital, Akita, 
      010-8543, Japan.
FAU - Tanegashima, Tokiyoshi
AU  - Tanegashima T
AD  - Department of Urology, Graduate School of Medical Sciences, Kyushu University, 
      3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
FAU - Narita, Shintaro
AU  - Narita S
AD  - Department of Urology, Graduate School of Medicine, Akita University, Akita, 
      010-8543, Japan.
FAU - Yamamoto, Yoshiaki
AU  - Yamamoto Y
AD  - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, 
      755-8505, Japan.
FAU - Fujimoto, Naohiro
AU  - Fujimoto N
AD  - Department of Urology, School of Medicine, University of Occupational and 
      Environmental Health, Kitakyushu, 807-8556, Japan.
FAU - Ueda, Shohei
AU  - Ueda S
AD  - Department of Urology, Graduate School of Medical Sciences, Kyushu University, 
      3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
FAU - Takeuchi, Ario
AU  - Takeuchi A
AD  - Department of Urology, Graduate School of Medical Sciences, Kyushu University, 
      3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
FAU - Numakura, Kazuyuki
AU  - Numakura K
AD  - Department of Urology, Graduate School of Medicine, Akita University, Akita, 
      010-8543, Japan.
FAU - Habuchi, Tomonori
AU  - Habuchi T
AD  - Department of Urology, Graduate School of Medicine, Akita University, Akita, 
      010-8543, Japan.
FAU - Matsuyama, Hideyasu
AU  - Matsuyama H
AD  - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, 
      755-8505, Japan.
FAU - Eto, Masatoshi
AU  - Eto M
AD  - Department of Urology, Graduate School of Medical Sciences, Kyushu University, 
      3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
FAU - Shiota, Masaki
AU  - Shiota M
AUID- ORCID: 0000-0002-3306-4858
AD  - Department of Urology, Graduate School of Medical Sciences, Kyushu University, 
      3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. 
      shiota.masaki.101@m.kyushu-u.ac.jp.
LA  - eng
GR  - 21K06592/Japan Society for the Promotion of Science/
GR  - 19K18551/Japan Society for the Promotion of Science/
PT  - Journal Article
DEP - 20210811
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (BCG Vaccine)
RN  - 0 (Biomarkers)
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Alleles
MH  - BCG Vaccine/therapeutic use
MH  - Biomarkers
MH  - Biopsy
MH  - Disease Management
MH  - Disease Susceptibility
MH  - *Genotype
MH  - HLA Antigens/*genetics/immunology
MH  - Homozygote
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Liquid Biopsy
MH  - Neoplasm Invasiveness
MH  - Prognosis
MH  - Recurrence
MH  - Treatment Outcome
MH  - Urinary Bladder Neoplasms/*genetics/mortality/*pathology/therapy
PMC - PMC10991975
OTO - NOTNLM
OT  - Bacillus Calmette-Guerin
OT  - Human leukocyte antigen
OT  - Immunotherapy
OT  - Intravesical recurrence
OT  - Non-muscle-invasive bladder cancer
COIS- Shintaro Narita received honoraria from Janssen Pharmaceutical, Bayer Yakuhin, 
      AstraZeneca, Takeda Pharmaceutical, Sanofi, and Astellas Pharma. Tomonori Habuchi 
      received honoraria from Janssen Pharmaceutical, Takeda Pharmaceutical, Astellas 
      Pharma, Daiichi Sankyo, AstraZeneca, Sanofi, and Bayer Yakuhin, and research 
      funding support from Takeda Pharmaceutical, Astellas Pharma, Daiichi Sankyo, 
      Sanofi, and Bayer Yakuhin. Masatoshi Eto received honoraria from Ono 
      Pharmaceutical, Takeda Pharmaceutical, Novartis Pharma, Pfizer, Bristol-Myers 
      Squibb, Janssen Pharmaceutical, MSD, and Merck Biopharma, and research funding 
      support from Sanofi, Bayer Yakuhin, Astellas Pharma., Ono Pharmaceutical., and 
      Takeda Pharmaceutical. Masaki Shiota received honoraria from Janssen 
      Pharmaceutical, AstraZeneca, and Astellas Pharma, and research funding support 
      from Daiichi Sankyo.
EDAT- 2021/08/12 06:00
MHDA- 2022/03/01 06:00
PMCR- 2021/08/11
CRDT- 2021/08/11 12:22
PHST- 2021/06/03 00:00 [received]
PHST- 2021/08/04 00:00 [accepted]
PHST- 2021/08/12 06:00 [pubmed]
PHST- 2022/03/01 06:00 [medline]
PHST- 2021/08/11 12:22 [entrez]
PHST- 2021/08/11 00:00 [pmc-release]
AID - 10.1007/s00262-021-03032-0 [pii]
AID - 3032 [pii]
AID - 10.1007/s00262-021-03032-0 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2022 Mar;71(3):727-736. doi: 
      10.1007/s00262-021-03032-0. Epub 2021 Aug 11.